In two patients with metastatic breast cancer treated at dose level 2, tumour stabilisation that lasted >6 months exceeded the duration of tumour stabilisation previously recorded with docetaxel therapy (3.7 and 3.5 months).
Although there was no statistical correlation between dose and frequency and/or duration of disease stabilisation, the observation was that at doses of and exceeding 1500 mg BID more prolonged disease stabilisation was observed.
Among 27 patients achieving SD, median duration of disease stabilisation was 100.0 days (3.3 months).
Nine patients experienced stable disease (SD) as best response that lasted >12 weeks and in three cases, the duration of the stabilisation was at least 6 months.
Interim results of trials of oral ridaforolimus for advanced endometrial cancer suggest ridaforolimus provides a response rate similar to that of everolimus but with a higher rate and a slightly longer duration of disease stabilisation (Table 4) (Colombo et al, 2007; Mackay et al, 2011; Oza et al, 2011b; ARIAD Pharmaceuticals Inc., 2012).
Three patients with renal carcinoma had SD at 16 weeks; the durations of disease stabilisation for these patients were 204, 219 and 337 days.
The secondary efficacy variables were the duration of response and stabilisation, time to progression, time to treatment failure and the overall survival.
The median duration of response and disease stabilisation was 4.4 months.
Again, no significant differences in duration of response and disease stabilisation, time to treatment failure, time to progression or survival were observed.
The secondary objectives were to determine the time to progression and treatment failure, duration of response and disease stabilisation, and survival.
